HC Wainwright Cuts Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $100.00

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price objective trimmed by HC Wainwright from $110.00 to $100.00 in a report published on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q1 2027 earnings at ($0.40) EPS, Q2 2027 earnings at ($0.02) EPS, Q3 2027 earnings at $0.33 EPS, Q4 2027 earnings at $0.68 EPS and FY2027 earnings at $0.59 EPS.

Several other research analysts have also commented on RYTM. Telsey Advisory Group set a $143.00 price objective on shares of Rhythm Pharmaceuticals in a report on Thursday, March 12th. Guggenheim lifted their target price on shares of Rhythm Pharmaceuticals from $140.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Bank of America reduced their price target on shares of Rhythm Pharmaceuticals from $145.00 to $139.00 and set a “buy” rating on the stock in a research report on Tuesday. Needham & Company LLC decreased their price target on shares of Rhythm Pharmaceuticals from $139.00 to $130.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Citigroup lowered their price objective on shares of Rhythm Pharmaceuticals from $136.00 to $131.00 and set a “buy” rating for the company in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Rhythm Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $131.13.

Rhythm Pharmaceuticals Stock Performance

Shares of RYTM stock opened at $87.45 on Wednesday. Rhythm Pharmaceuticals has a fifty-two week low of $45.90 and a fifty-two week high of $122.20. The firm has a market cap of $5.97 billion, a P/E ratio of -28.12 and a beta of 2.06. The business’s 50 day moving average price is $99.04 and its 200-day moving average price is $102.49.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its earnings results on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.06. The company had revenue of $57.25 million during the quarter, compared to the consensus estimate of $56.16 million. Rhythm Pharmaceuticals had a negative return on equity of 266.56% and a negative net margin of 103.57%.The firm’s revenue for the quarter was up 36.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.72) earnings per share. As a group, equities analysts predict that Rhythm Pharmaceuticals will post -4.32 EPS for the current year.

Insider Activity at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, CFO Hunter C. Smith sold 4,385 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $101.26, for a total value of $444,025.10. Following the completion of the transaction, the chief financial officer directly owned 110,512 shares in the company, valued at $11,190,445.12. This represents a 3.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Christopher Paul German sold 5,614 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total value of $502,789.84. Following the sale, the chief accounting officer directly owned 160 shares in the company, valued at approximately $14,329.60. This represents a 97.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 27,267 shares of company stock worth $2,719,955 in the last ninety days. Insiders own 6.10% of the company’s stock.

Institutional Trading of Rhythm Pharmaceuticals

Several institutional investors have recently made changes to their positions in RYTM. Xponance LLC lifted its holdings in shares of Rhythm Pharmaceuticals by 2.6% in the fourth quarter. Xponance LLC now owns 4,269 shares of the company’s stock worth $457,000 after buying an additional 107 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Rhythm Pharmaceuticals by 4.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,568 shares of the company’s stock valued at $259,000 after acquiring an additional 110 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in Rhythm Pharmaceuticals by 39.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 399 shares of the company’s stock valued at $43,000 after acquiring an additional 113 shares during the last quarter. Captrust Financial Advisors lifted its stake in Rhythm Pharmaceuticals by 0.7% in the 2nd quarter. Captrust Financial Advisors now owns 17,471 shares of the company’s stock worth $1,104,000 after purchasing an additional 114 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in Rhythm Pharmaceuticals by 48.6% in the 4th quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock worth $39,000 after purchasing an additional 118 shares in the last quarter.

Rhythm Pharmaceuticals News Summary

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: FDA approved IMCIVREE (setmelanotide) for acquired hypothalamic obesity — the first and only therapy for this rare condition, expanding the label and potential patient population, which materially strengthens Rhythm’s commercial runway. Read More.
• Positive Sentiment: Rhythm named PANTHERx® Rare as the exclusive U.S. specialty pharmacy partner for the expanded IMCIVREE indication — this should improve patient access, distribution scale and support launch execution. Read More.
• Neutral Sentiment: Some brokers still assign above-current price targets (one report references a $133.19 consensus PT from select brokers), indicating divergent views on upside even after recent weakness. Read More.
• Neutral Sentiment: Investor/earnings-call coverage and transcripts are circulating (discussing the FDA approval and commercialization plans), useful for modeling uptake but not a direct catalyst on their own. Read More.
• Negative Sentiment: HC Wainwright reduced EPS forecasts across multiple quarters and cut its FY2027 outlook and price target (now $100) — the cuts lower near-term earnings expectations and likely contributed to selling pressure despite the firm maintaining a Buy rating. Read More.
• Negative Sentiment: Multiple brokers published pessimistic forecasts or lowered expectations (Bank of America, RBC, Needham, Citizens JMP), creating additional downward pressure and a wider dispersion of analyst views. Read More. Read More. Read More. Read More.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.